CN102149683B - 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途 - Google Patents

1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途 Download PDF

Info

Publication number
CN102149683B
CN102149683B CN2010800025776A CN201080002577A CN102149683B CN 102149683 B CN102149683 B CN 102149683B CN 2010800025776 A CN2010800025776 A CN 2010800025776A CN 201080002577 A CN201080002577 A CN 201080002577A CN 102149683 B CN102149683 B CN 102149683B
Authority
CN
China
Prior art keywords
salt
benzyl
trifluoromethylpyridin
flumethiazine
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2010800025776A
Other languages
English (en)
Chinese (zh)
Other versions
CN102149683A (zh
Inventor
胡高云
陶立坚
陈军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central South University
Original Assignee
Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central South University filed Critical Central South University
Priority to CN2010800025776A priority Critical patent/CN102149683B/zh
Publication of CN102149683A publication Critical patent/CN102149683A/zh
Application granted granted Critical
Publication of CN102149683B publication Critical patent/CN102149683B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800025776A 2009-05-25 2010-05-24 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途 Active CN102149683B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010800025776A CN102149683B (zh) 2009-05-25 2010-05-24 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200910043502.1 2009-05-25
CN200910043502 2009-05-25
PCT/CN2010/073131 WO2010135976A1 (zh) 2009-05-25 2010-05-24 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途
CN2010800025776A CN102149683B (zh) 2009-05-25 2010-05-24 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途

Publications (2)

Publication Number Publication Date
CN102149683A CN102149683A (zh) 2011-08-10
CN102149683B true CN102149683B (zh) 2013-10-02

Family

ID=43222161

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800025776A Active CN102149683B (zh) 2009-05-25 2010-05-24 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途

Country Status (9)

Country Link
US (1) US8377932B2 (https=)
EP (1) EP2474533B1 (https=)
JP (1) JP5722883B2 (https=)
KR (1) KR101478133B1 (https=)
CN (1) CN102149683B (https=)
AU (1) AU2010252451B2 (https=)
DK (1) DK2474533T3 (https=)
ES (1) ES2536200T3 (https=)
WO (1) WO2010135976A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
JP5924984B2 (ja) * 2012-03-06 2016-05-25 国立大学法人東京農工大学 トリフルオロメチルピリジノン化合物およびその製造方法
BR112014030284B1 (pt) 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR20150018127A (ko) * 2013-08-09 2015-02-23 삼성전자주식회사 디스플레이 장치 및 그 방법
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN106466318B (zh) * 2015-08-21 2019-01-01 中南大学 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
CN107663167A (zh) * 2016-10-19 2018-02-06 广州南新制药有限公司 1‑（取代苄基）‑5‑三氟甲基‑2(1h)‑吡啶酮盐酸盐的晶型及制备方法
CN107652228B (zh) * 2016-10-28 2020-04-14 广州南新制药有限公司 抗肾纤维化药物1-（取代苄基）-5-三氟甲基-2(1h)-吡啶酮盐酸盐的合成方法
CN113456642B (zh) * 2021-07-09 2022-09-06 中南大学 一种美氟尼酮在制备治疗急性肾损伤药物中的应用
WO2023168649A1 (zh) * 2022-03-10 2023-09-14 广州南新制药有限公司 一种美氟尼酮盐酸盐的制备方法
WO2023168650A1 (zh) * 2022-03-10 2023-09-14 广州南新制药有限公司 一种美氟尼酮晶型的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1386737A (zh) * 2002-06-11 2002-12-25 中南大学湘雅医学院 抗纤维化吡啶酮药物及其生产工艺方法
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
GB8523126D0 (en) * 1985-09-19 1985-10-23 Ici Plc Aryl pyridones
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
GB8825314D0 (en) 1988-10-28 1988-11-30 Ici Plc Chemical compounds
GB9006479D0 (en) 1989-04-17 1990-05-23 Ici Plc Novel compounds
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5238906A (en) 1990-11-27 1993-08-24 Sumitomo Chemical Company, Limited Pyridone derivatives and use
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
ATE448784T1 (de) * 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
US7166603B2 (en) * 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
GB0324159D0 (en) * 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
CN100358872C (zh) 2003-11-14 2008-01-02 上海睿星基因技术有限公司 吡啶酮衍生物及其应用
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
CN101237869A (zh) * 2005-05-10 2008-08-06 英特芒尼公司 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
KR20080076968A (ko) 2005-11-23 2008-08-20 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하는 방법
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
CN101371833A (zh) 2007-08-23 2009-02-25 中南大学 1-芳基-2(1h)-吡啶酮类化合物在制备治疗皮肤瘙痒药物中的应用
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AP2011005824A0 (en) 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1386737A (zh) * 2002-06-11 2002-12-25 中南大学湘雅医学院 抗纤维化吡啶酮药物及其生产工艺方法
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途

Also Published As

Publication number Publication date
AU2010252451B2 (en) 2014-04-03
CN102149683A (zh) 2011-08-10
AU2010252451A1 (en) 2011-12-15
KR101478133B1 (ko) 2014-12-31
ES2536200T3 (es) 2015-05-21
KR20120060785A (ko) 2012-06-12
EP2474533B1 (en) 2015-02-25
EP2474533A1 (en) 2012-07-11
WO2010135976A1 (zh) 2010-12-02
JP5722883B2 (ja) 2015-05-27
US8377932B2 (en) 2013-02-19
HK1166791A1 (en) 2012-11-09
DK2474533T3 (en) 2015-05-18
JP2012527488A (ja) 2012-11-08
EP2474533A4 (en) 2012-11-14
US20120129859A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
CN102149683B (zh) 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途
CN102149682B (zh) 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途
PT1877390E (pt) Compostos benzisoxazole-piridina e métodos para a sua utilização
KR101264444B1 (ko) 록사핀 유사체 및 이것의 사용 방법
TWI293301B (en) A1 adenosine receptor antagonists
TWI324066B (en) A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor
KR20070045272A (ko) 2-페닐피리딘 유도체
AU3219600A (en) Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
PT86082B (pt) Processo para a preparacao de agentes di-hidropiridinicos anti-alergicos e anti-inflamatorios
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
JP7681599B2 (ja) 選択的ｃｄｋ４／６阻害剤のがん治療薬
JP2011516444A (ja) Ｈｄｌ−コレステロール上昇剤としての２−トリフルオロメチルニコチンアミド誘導体
WO2023183936A2 (en) Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof
CN119285617B (zh) 1,3,5-三取代吲哚衍生物及其应用
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
CN119241539A (zh) 含吡唑并哌啶（酮）衍生物及其制备方法和应用
HK1166791B (en) Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications
BRPI0610258A2 (pt) composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto
HK1241362B (en) Compounds and methods for inducing browning of white adipose tissue

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant